Introduction
============

Natural killer/T-cell lymphoma (NKTCL) is a rare haematological malignancy which is typically extranodal, and it has two main subtypes: nasal and nasal-type. It is characterised by prominent necrosis and cytotoxic phenotype associated with the Epstein-Barr virus \[[@ref1]\]. NKTCL is more prevalent in Asia, Central, and South America \[[@ref2]--[@ref9]\]. The upper aerodigestive tract (nasal cavity, nasopharynx, paranasal sinuses, palate) is commonly involved, with the nasal cavity as the prototype. Extranodal sites of involvement include the skin, soft tissue, and testicles \[[@ref3], [@ref10]--[@ref14]\]. Some cases may also be accompanied by secondary nodal involvement \[[@ref15]\].

The survival of NKTCL is poor \[[@ref13]\]. Adverse prognostic factors associated with worse survival have been described, such as non-nasal primary, clinical staging, nodal involvement, Ki-67 expression, the International Prognostic Index (IPI), the Korean Prognostic Index (KPI), large cells, local tumour invasiness, and circulating EBV-DNA levels among others \[[@ref16]--[@ref25]\]. However, in our country (Peru), there are no studies assessing prognosis factors in these patients.

The aim of this retrospective study is to describe predictors of OS and PFS as well as clinical and pathological features of patients with NKTCL treated at our centre.

Methods
=======

Patients
--------

The study population included all newly diagnosed patients \>13 years of age with a pathological confirmation of NKTCL seen at the National Institute of Neoplastic Diseases (INEN) in Lima,Peru between January 2002 and December 2011. Patients with other previous cancers, positive serology for HIV, and diagnosis of aggressive NK cell leukaemia, or incomplete MRs were excluded. The diagnosis of NKTCL was based on the WHO 2008 classification of haematopoietic and lymphoid tissues \[[@ref1]\]. All cases were reviewed by an expert panel in lymphomas to confirm diagnosis.

Laboratory findings and staging
-------------------------------

Haematological tests, including complete blood count, liver, and renal function tests, and LDH were performed. Local tumour invasion was defined differently according to the two subtypes. The nasal NKTL was defined in accordance with 7th ed., 2010 TNM classification of the American Joint Committee of Cancer. Any nasal NKTCL with T3 or greater were considered as local invasive in the analysis. For non-nasal NKTCL, the definition of local invasiveness differed according to primary sites. For gastrointestinal NKTCL, local invasiveness referred to T4 lesion in TNM system. In NKTCL primarily involving soft tissue such as muscle or skin, invasion of neurovascular structure or bone invasion was considered as local invasion. Regional nodal involvement was defined as the invasion of lymph nodes corresponding to N1, N2, or N3 of the primary lesion based upon TNM staging system. Accordingly, M1 nodes at TNM system were not categorised as regional lymph nodes in the analysis \[[@ref16]\].

The staging was based on modified System Cotswolds Ann Arbor \[[@ref26]\]. Performance status was evaluated according to the Eastern Cooperative Oncology Group (ECOG) scale \[[@ref27]\]. The response was evaluated based on the revised response criteria for lymphomas \[[@ref28]\].

Statistical analysis
--------------------

A descriptive analysis of the information through frequencies, percentages, and measures of central tendency were performed. OS was defined as the time from the date of diagnosis to date of last visit or death from any cause, and PFS from the initiation of treatment to disease relapse/progression, last follow-up or death from any cause, whichever occurred first. The overall and PFS were estimated with the Kaplan-Meier method and differences were tested using the log-rank test. The Cox proportional hazard models were used to identify predictors of survival of NK/T-cell lymphomas. A level of p \<0.05 was considered for a statistical significance. The multivariate analysis was performed with all factors with statistical significance in the univariate analysis. SPSS version 22.0 was used for statistical analysis.

Results
=======

Patient characteristics
-----------------------

A total of 226 patients were seen at our centre during the study period, according to the database of the Department of Epidemiology, 212 records were retrieved, 37 did not receive chemotherapy, 15 had previous treatment, 5 were younger than 13 years, and 2 had metacronic neoplasms. Finally 153 cases were reviewed for analysis. This study was approved by the Institutional Review Board at our institution. The clinical characteristics of the 153 patients are outlined in [Table 1](#table1){ref-type="table"}. The majority of the patients were primary nasal (126, 82.4%). The non-nasal primary (27, 17.4%) included primary lesions at the following sites: Waldeyer's ring (n = 5), skin (n = 5), oropharynx (n = 3), hard palate (n = 3), soft tissue (n = 3), splenic (n = 1), tongue (n = 1), gastrointestinal tract (n = 1), alveolar ridge (n = 1), cervical lymph node (n = 1), inguinal lymph node (n = 1), larynx (n = 1), and hypopharynx (1).

Treatment
---------

Radiotherapy only was the treatment used in 79 patients (51.6%), chemotherapy only in 25 (16.3%), chemotherapy followed by radiotherapy in 33 (21.6%), radiotherapy followed by chemotherapy in 14 (9.2%), and concurrent chemoradiotherapy in 2 (1.3%) ([Table 1](#table1){ref-type="table"}). The early stages were treated with radiotherapy only in 77 cases (57.5%) (nasal = 73), chemotherapy only in 11 (8.2%) (nasal = 9), chemotherapy followed by radiotherapy in 32 cases (23.9%) (nasal = 22), radiotherapy followed by chemotherapy in 12 (8.9%) (nasal = 11), concurrent chemoradiotherapy in 2 (1.5%) (nasal = 2). None of these patients underwent haematopoietic stem cell transplantation. The advanced stages were treated with radiotherapy only in two cases (10.5%) (nasal = 1), chemotherapy only in 14 (73.7%) (nasal = 6), and chemotherapy followed by radiotherapy in one case (5.3%) (non-nasal = 1), radiotherapy followed by chemotherapy in two cases (10.5%) (nasal = 2).

Chemotherapy regimen used was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in seven patients (early stages n = 2 , advanced stages n = 5) and CHOEP-14 (CHOP + etoposide) in 18 (early stages n = 9) patients. No one patient received SMILE regimen (dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide) as it was included as a salvage treatment just at the end of 2013. The chemotherapy regimens used either as monotherapy, prior, concurrent, or followed by radiotherapy were CHOP in 33 (44.5%), CHOEP-14 in 40 (54.1%), and other regimen in one case (1.4%), totalling 74 patients with this type of treatment.

Twenty-five patients received chemotherapy only (early stages n = 11), ranging the number of cycles of chemotherapy between 1 and 8 with a median of 2.5 cycles. Among the patients in early stages receiving chemotherapy followed by radiotherapy with number of cycles ranging between 1 and 8, we find 69.6% (23 out of 33) received six cycles. It was also noted that only one patient with advanced disease received this modality of treatment.

Treatment response
------------------

The early stages had response rates as follows: CR n = 92 (68.7% ) (stage I = 68, stage II = 24) PR n = 16 (11.9%) (stage I = 10, Stage II = 6), SD n = 3 (2.2%) (stage I = 2, stage II = 1), PD n = 23 (17.2%) (stage I = 11, stage II = 12). The advanced diseases had response rates as follows: CR n = 7 (36.8%) (stageIII = 1, stage IV = 6), PR n = 5 (26.4%) (stage IV = 5), SD n = 0, PD n = 7 (36.8%) (stage III = 1, stage IV = 6).

Progression-free survival
-------------------------

With a median follow-up time of 18 months, the median PFS time was 20 months (95% CI 0--41), and the five year PFS rate was 42.6%. The variables that showed statistical significance towards a worse outcome in the univariate analysis were male sex, non-nasal primary site, advanced clinical stages, presence of B symptoms, poor performance status (PS), and nodal involvement. The median PFS for the nasal primary was 79 months (95% CI 14--143) and the five year PFS was 50.9% as shown in [Figure 1](#figure1){ref-type="fig"} and [Table 2](#table2){ref-type="table"}. The six variables with statistical significance were studied by multivariate analysis, showing that the only independent poor prognostic factor was primary non-nasal site (HR = 2.40, 95% CI = 1.43--4.02, P = 0.01) ([Table 2](#table2){ref-type="table"}).

Overall survival
----------------

Seventy-five patients (49%) had died by the time of the analysis. With a median follow-up of 48 months (1--143 months). The median OS time was 49 months (95% CI 0--98) and the five year OS rate was 48.9% ([Figure 2](#figure2){ref-type="fig"}). The factors that showed statistical significance towards a worse outcome in the univariate analysis were non-nasal primary site, advanced clinical stage, presence of B symptoms, increased LDH, nodal involvement and local tumour invasion. For nasal primary the median OS time was not reached and the five year OS rate was 55.8% as shown in [Table 3](#table3){ref-type="table"} and [Figure 3](#figure3){ref-type="fig"}. The multivariate analysis showed that the only poor prognostic factor was primary non-nasal site (HR = 2.57, 95% CI = 1.37--4.83, P = 0.03) ([Table 3](#table3){ref-type="table"}).

We performed a sub-analysis for early disease and we found the median OS for nasal primary (117, 87.3%) was not reached and that for non-nasal primary (17, 12.6%) was 17 months, p = 0.003. In the multivariate analysis we identified three factors for poor prognosis, non-nasal site (HR = 3.1, 95% CI 1.50--6.37 p = 0.002), presence of B symptoms (HR = 1.86, 95% CI 1.037--3.34, p 0.037), and DHL \> normal (HR = 1.84, 95% CI 1.04--3.27, p = 0.035).

Discussion
==========

We present here 153 NKTCL patients who fulfilled our selection criteria diagnosed over a period of ten years. To the best of our knowledge it is the largest Latin American study in NKTCL patients \[[@ref4]--[@ref8]\] and the second largest in the whole American continent \[[@ref9]--[@ref12]\]. The number of patients were similar to some seen in multicentre studies \[[@ref2], [@ref13], [@ref15], [@ref20]--[@ref22], [@ref32]--[@ref36]\]. The present study shows that the clinical characteristics of nasal NKTCL in Peru are similar to those described in other Latin American as well as Asian and Western countries \[[@ref2], [@ref3], [@ref6], [@ref8], [@ref9], [@ref29], [@ref30]\]. The treatment used in our population was according to the clinical staging, with radiotherapy only or concurrent with chemotherapy for early stages, and chemotherapy only for advanced disease, as is described in the international literature \[[@ref31]\]. L-asparaginase-based regimen (SMILE treatment) was not part of the treatment, as this was incorporated in our institution just in 2013 \[[@ref37]\].

In this series, the PFS was 20 months which is similar to reported by Huang *et al* at 18 months \[[@ref21]\]. However, the five year PFS was 29.8% which is lower than our study where the five year PFS was 42.6%. This discrepancy might be because of a lower proportion of patients with presence of B symptoms in our study (36% versus 54%, respectively) and also could have influenced the higher percentage of patients with early stages in our study (83% versus 79.5%, respectively) . In contrast, Lee *et al* \[[@ref16]\] showed a five year relapse-free survival (RFS) of 60%. This result is different because this was calculated on patients who had achieved complete remission.

In our study, we show that patients with NKTCL have poor survival, with a median OS of 49 months. In other studies, the median OS has ranged between 30 and 50 months \[[@ref2], [@ref16], [@ref21], [@ref34]\]. However, when we consider the survival for non-nasal NKTCL this was nine months, different from data reported by Au *et al* \[[@ref3]\] where extranasal cases had a median OS of four months. This was probably because 19% of those patients did not receive treatment because of advanced disease unlike our study where all patients received treatment.

Regarding the cumulative probability of survival at five years, our study shows a 49% OS rate, whereas in other studies it ranged between 39% and 50%. \[[@ref13], [@ref16], [@ref21], [@ref34], [@ref37], [@ref38]\]. When evaluating the non-nasal primary this was 16% which is comparable to the study of Au *et al* \[[@ref3]\]. Only a non-nasal primary site was an independent adverse predictor in the multivariate analysis which we find is also the same variable identified in other studies \[[@ref3], [@ref12], [@ref16], [@ref32]\]. The primary site of this type of lymphoma had been evaluated previously but with the term upper aerodigestive tract NKTCL. This included lymphomas confined to nasal cavity, nasopharynx, larynx, pharynx, and oral cavity \[[@ref16]\]. In our study nasal type refers only to nasal cavity.

In our study, we found that the primary site is more important than clinical stage as independent prognostic risk factor, and this finding was reported by Au *et al*'s study. Even non-nasal primary with apparently localised disease had poor prognosis \[[@ref3]\]. The biological distinction between these two subgroups remains unknown, hence necessitating future studies with genetic and epigenetic profiling.

Other prognostic factors have been evaluated in NKTCL patients such as Ki-67 expression, EBV viral load, lymphocyte and monocyte counts \[[@ref19], [@ref21], [@ref25], [@ref33]\]. In the last years c-Myc expression, beta-2 microglobulin, CD30-CD38 expression, the albumin to globulin ratio \[[@ref38]--[@ref44]\], CD56 expression, higher levels of HLA-DR negative, CD33, CD11b myeloid-derived suppressor cells (MDSCs), CD14 monocytic MDSCs, independent adverse prognostic scores have also been used for evaluation \[[@ref45]\]. However, in our study we could not evaluate these factors either because of incomplete baseline data or because of lack of tests for these factors in our centre.

Conclusion
==========

In conclusion, in Peru the OS for NK/T-cell lymphoma is similar to other Latin American as well as Asian countries. The results suggest that non-nasal NKTCL is the only poor prognostic factor of OS and PFS which we find is even more important than the clinical staging itself. This poor prognostic factor is seen in early stages as well. It is important to conduct multicentre prospective studies including the most important clinical, laboratorial, pathological, and viral prognostic factors in order to make an accurate prognostic index.
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###### Clinical and pathological characteristics.

  --------------------------------------------------------------------
  Characteristics                  N               \%
  -------------------------------- --------------- -------------------
  Age, years, Median/range         40/\[14--84\]   

  Age intervals\                   131/22          85.6/14.4
  ≤60 years old/\>60 years old                     

  Sex (male/female)                98/55           64.1/35.9

  Primary site\                    126/27          82.4/17.4
  Nasal/Non-nasal                                  

  Stage\                           \               \
  Early (I, II)\                   134 (91/43)\    87.6 (59.5/28.1)\
  Advanced (III, IV)               19 (2/17)\      12.4 (1.3/11.1)

  B Symptoms\                      55/98           35.9/64.1
  Yes/No                                           

  LDH\                             58/83/12        37.9/54.2/7.8
  \>Normal/\<Normal/No available                   

  Performance Status (ECOG)\       138/15/0/0      90.2/9.8/0/0
  (1,2,3,4)                                        

  Regional nodal involvement\      60/93           39.2/60.8
  Yes/No                                           

  Local tumour invasion\           44/109          28.8/71.2
  Yes/no                                           

  Type of treatment                                

  Chemotherapy only                25              16.3

  Radiotherapy only                79              51.6

  Chemo-radiotherapy               49              32.1
  --------------------------------------------------------------------

###### PFS according to patients features and univariate/multivariate analysis of prognostic factors.

  ------------------------------------------------------------------------------------------------------------------------------
  Characteristics              N        Median, months   Five year\         Univariate analysis   Multivariate analysis   
                                                         survival rate, %                                                 
  ---------------------------- -------- ---------------- ------------------ --------------------- ----------------------- ------
  Age, years                                                                                                              

  ≤60                          131      17               41.9                                                             

  \>60                         22       40               45.5               0.376                                         

  Sex (male/Female)            98/55    12/79            37.5/51.3          0.033                                         

  Primary site                                                                                                            

  Nasal                        126      79               50.9                                     2.40 (1.43--4.02)       0.01

  Non-nasal                    27       9                4.2                \<0.001                                       

  Stage                                                                                                                   

  Early (I--II)                134      33               46.7                                                             

  Advanced (III--IV)           19       7                14                 0.002                                         

  B symptoms                                                                                                              

  Yes                          55       7                33.2                                                             

  No                           98       40               50.6               0.016                                         

  PS                                                                                                                      

  1                            138      33               44.5                                                             

  2                            15       4                26.7               0.028                                         

  LDH                                                                                                                     

  \>normal                     58       11               38.1                                                             

  ≤normal                      83       45               50.0               0.060                                         

  Regional nodal involvement                                                                                              

  Yes                          60       7                27.9                                                             

  No                           93       79               51.9               0.005                                         

  Local tumour invasion\       \        \                \                  \                                             
  Yes/No                       44/109   12/40            31.7/46.9          0.083                                         
  ------------------------------------------------------------------------------------------------------------------------------

NR = Not reached, PFS = progression-free survival

###### Overall survival, according to patient features and univariate/multivariate analysis of prognostic factors.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics              N       Median, months                                  Five year\         Univariate analysis   Multivariate analysis   
                                                                                       survival rate, %                                                 
  ---------------------------- ------- ----------------------------------------------- ------------------ --------------------- ----------------------- ------
  ≤60                          131     49                                              49                                                               

  \>60                         22      49                                              48.3               0.572                                         

  Sex (male/female)            98/55   40/NR[^(\*)^](#table3_1){ref-type="table-fn"}   45.8/54.1          0.106                                         

  Primary site                                                                                                                                          

  Nasal                        126     NR[^(\*)^](#table3_1){ref-type="table-fn"}      55.8                                                             

  Non-nasal                    27      11                                              16.0               \<0.001               2.57 (1.37--4.83)       0.03

  Stage                                                                                                                                                 

  Early (I--II)                134     92                                              52.8                                                             

  Advance (III--IV)            19      8                                               21.1               0.005                                         

  B Symptoms (yes/no)          55/98   13/103                                          37.6/55.2          0.014                                         

  PS                                                                                                                                                    

  1                            138     62                                              50.1                                                             

  2                            15      8                                               40.0               0.160                                         

  LDH                                                                                                                                                   

  \>normal                     58      17                                              43.8                                                             

  ≤normal                      83      NR[^(\*)^](#table3_1){ref-type="table-fn"}      57.9               0.018                                         

  Regional nodal involvement                                                                                                                            

  Yes                          60      11                                              35.4                                                             

  No                           93      NR[^(\*)^](#table3_1){ref-type="table-fn"}      57.5               0.002                                         

  Local tumour invasion                                                                                                                                 

  Yes                          44      13                                              39.3                                                             

  No                           109     103                                             52.5               0.040                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Not reached
